P. Hoth

TP53 Mutations and Outcome After Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial of the GCLLSG.

H. Döhner, U. Jäger, M. Hallek, 2009 .

Treatment resistance in chronic lymphocytic leukemia–the role of the p53 pathway

H. Döhner, S. Stilgenbauer, T. Zenz, 2009, Leukemia & lymphoma.

Genetics of Patients with F-Refractory CLL or Early Relapse After FC or FCR: Results From the CLL8 Trial of the GCLLSG

H. Döhner, P. Lichter, G. Fingerle-Rowson, 2010 .

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.

M. Cazzola, L. Bullinger, K. Döhner, 2012, Blood.

TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations

A. Pettitt, H. Döhner, M. Hallek, 2010, Leukemia.